JP5738871B2 - β３アドレナリン作動性受容体アゴニスト及び抗ムスカリン剤を用いる併用療法 - Google Patents
β３アドレナリン作動性受容体アゴニスト及び抗ムスカリン剤を用いる併用療法 Download PDFInfo
- Publication number
- JP5738871B2 JP5738871B2 JP2012533204A JP2012533204A JP5738871B2 JP 5738871 B2 JP5738871 B2 JP 5738871B2 JP 2012533204 A JP2012533204 A JP 2012533204A JP 2012533204 A JP2012533204 A JP 2012533204A JP 5738871 B2 JP5738871 B2 JP 5738871B2
- Authority
- JP
- Japan
- Prior art keywords
- mmol
- methyl
- tert
- agonist
- phenyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/221—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having an amino group, e.g. acetylcholine, acetylcarnitine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Engineering & Computer Science (AREA)
- Urology & Nephrology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US24938609P | 2009-10-07 | 2009-10-07 | |
| US61/249,386 | 2009-10-07 | ||
| PCT/US2010/050328 WO2011043942A1 (en) | 2009-10-07 | 2010-09-27 | Combination therapy using a beta 3 adrenergic receptor agonist and an antimuscarinic agent |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2013507363A JP2013507363A (ja) | 2013-03-04 |
| JP5738871B2 true JP5738871B2 (ja) | 2015-06-24 |
Family
ID=43857059
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012533204A Active JP5738871B2 (ja) | 2009-10-07 | 2010-09-27 | β３アドレナリン作動性受容体アゴニスト及び抗ムスカリン剤を用いる併用療法 |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20120202819A1 (https=) |
| EP (1) | EP2485595A4 (https=) |
| JP (1) | JP5738871B2 (https=) |
| KR (1) | KR20120093859A (https=) |
| CN (1) | CN102638987A (https=) |
| AU (1) | AU2010303811B2 (https=) |
| BR (1) | BR112012007829A2 (https=) |
| CA (1) | CA2774992A1 (https=) |
| IL (1) | IL218756A0 (https=) |
| IN (1) | IN2012DN02782A (https=) |
| MX (1) | MX2012004134A (https=) |
| NZ (1) | NZ599233A (https=) |
| RU (1) | RU2012118668A (https=) |
| WO (1) | WO2011043942A1 (https=) |
| ZA (1) | ZA201202520B (https=) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9907767B2 (en) | 2010-08-03 | 2018-03-06 | Velicept Therapeutics, Inc. | Pharmaceutical compositions and the treatment of overactive bladder |
| AU2011285928B9 (en) * | 2010-08-03 | 2018-08-02 | B3Ar Therapeutics, Inc. | Combinations of beta - 3 adrenergic receptor agonists and muscarinic receptor antagonists for treating overactive bladder |
| US9522129B2 (en) | 2010-08-03 | 2016-12-20 | Velicept Therapeutics, Inc. | Pharmaceutical Combination |
| US8940763B2 (en) * | 2011-05-10 | 2015-01-27 | Theravida, Inc. | Combinations of solifenacin and salivary stimulants for the treatment of overactive bladder |
| ES2584427T3 (es) | 2011-10-27 | 2016-09-27 | Merck Sharp & Dohme Corp. | Proceso para la preparación de agonistas beta 3 y productos intermedios |
| WO2013062881A1 (en) * | 2011-10-27 | 2013-05-02 | Merck Sharp & Dohme Corp. | Process for making beta 3 agonists and intermediates |
| TW201338772A (zh) * | 2012-02-09 | 2013-10-01 | Altherx Inc | 藥學組合物 |
| RS59402B1 (sr) * | 2013-03-15 | 2019-11-29 | Merck Sharp & Dohme | Postupak za pripremu beta 3 agonista i međuproizvoda |
| CN105579057A (zh) * | 2013-07-23 | 2016-05-11 | 阿勒根公司 | 包含与β-3-肾上腺素能受体激动剂组合的去氨加压素的方法和组合物 |
| JP2017535567A (ja) | 2014-11-20 | 2017-11-30 | アラーガン、インコーポレイテッドＡｌｌｅｒｇａｎ，Ｉｎｃｏｒｐｏｒａｔｅｄ | アルファ−アドレナリン受容体拮抗薬と組み合わせたデスモプレシンを含む方法及び組成物 |
| HK1245117A1 (zh) | 2014-12-03 | 2018-08-24 | Velicept Therapeutics, Inc. | 使用调节释放索拉贝隆用於下尿路症状的组合物和方法 |
| US20180360845A1 (en) * | 2015-07-20 | 2018-12-20 | Chase Pharmaceuticals Corporation | Muscarinic combination of a selective m2-antagonist and a peripheral non-selective antagonist for treating hypocholinergic disorders |
| ES2967863T3 (es) | 2015-10-23 | 2024-05-06 | B3Ar Therapeutics Inc | Ion dipolar de solabegron y usos del mismo |
| WO2018039159A1 (en) * | 2016-08-22 | 2018-03-01 | Chase Pharmaceuticals Corporation | Muscarinic m2-antagonist combination |
| EP3634420A1 (en) | 2017-06-06 | 2020-04-15 | Urovant Sciences GmbH | Use of vibegron to treat overactive bladder |
| JP7670461B2 (ja) * | 2017-06-06 | 2025-04-30 | ウロバント サイエンシズ ゲゼルシャフト ミット ベシュレンクター ハフトゥング | 過活動膀胱の治療のためのビベグロンの投薬 |
| KR102735800B1 (ko) * | 2017-12-21 | 2024-11-28 | 교린 세이야쿠 가부시키가이샤 | 야간빈뇨 치료제 |
| SG11202103662VA (en) | 2018-12-05 | 2021-06-29 | Urovant Sciences Gmbh | Vibegron for the treatment of overactive bladder symptoms |
| CN115850286B (zh) * | 2022-12-05 | 2023-08-22 | 奥锐特药业(天津)有限公司 | 一种维贝格龙中间体及其制备方法 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2789076B1 (fr) * | 1999-02-02 | 2001-03-02 | Synthelabo | Derives de alpha-azacyclomethyl quinoleine, leur preparation et leur application en therapeutique |
| GB2356197A (en) * | 1999-10-12 | 2001-05-16 | Merck & Co Inc | Amide derivatives as beta 3 agonists |
| WO2003024483A1 (fr) * | 2001-09-11 | 2003-03-27 | Fujisawa Pharmaceutical Co., Ltd. | Potentialisateur d'effets inhibiteurs sur la frequence des mictions et l'incontinence urinaire |
| TWI295669B (en) * | 2002-10-30 | 2008-04-11 | Theravance Inc | Substituted 4-amino-1-(pyridylmethyl) piperidine and related compounds |
| US20040248979A1 (en) * | 2003-06-03 | 2004-12-09 | Dynogen Pharmaceuticals, Inc. | Method of treating lower urinary tract disorders |
| CA2580170A1 (en) * | 2004-10-18 | 2006-04-27 | Boehringer Ingelheim International Gmbh | Use of a beta-3 agonist for treating complaints of the prostate and the lower urogenital tract |
| AU2008233232A1 (en) * | 2007-03-29 | 2008-10-09 | Merck Sharp & Dohme Corp. | Combination therapy for the treatment-of lower urinary tract symptoms |
| PE20091825A1 (es) * | 2008-04-04 | 2009-12-04 | Merck & Co Inc | Hidroximetil pirrolidinas como agonistas del receptor adrenergico beta 3 |
-
2010
- 2010-09-27 WO PCT/US2010/050328 patent/WO2011043942A1/en not_active Ceased
- 2010-09-27 US US13/500,574 patent/US20120202819A1/en not_active Abandoned
- 2010-09-27 JP JP2012533204A patent/JP5738871B2/ja active Active
- 2010-09-27 BR BR112012007829A patent/BR112012007829A2/pt not_active IP Right Cessation
- 2010-09-27 MX MX2012004134A patent/MX2012004134A/es not_active Application Discontinuation
- 2010-09-27 NZ NZ599233A patent/NZ599233A/xx not_active IP Right Cessation
- 2010-09-27 AU AU2010303811A patent/AU2010303811B2/en not_active Ceased
- 2010-09-27 CN CN2010800550891A patent/CN102638987A/zh active Pending
- 2010-09-27 CA CA2774992A patent/CA2774992A1/en not_active Abandoned
- 2010-09-27 EP EP10822429.6A patent/EP2485595A4/en not_active Withdrawn
- 2010-09-27 IN IN2782DEN2012 patent/IN2012DN02782A/en unknown
- 2010-09-27 RU RU2012118668/13A patent/RU2012118668A/ru not_active Application Discontinuation
- 2010-09-27 KR KR1020127008961A patent/KR20120093859A/ko not_active Withdrawn
-
2012
- 2012-03-20 IL IL218756A patent/IL218756A0/en unknown
- 2012-04-05 ZA ZA2012/02520A patent/ZA201202520B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN102638987A (zh) | 2012-08-15 |
| KR20120093859A (ko) | 2012-08-23 |
| ZA201202520B (en) | 2012-12-27 |
| MX2012004134A (es) | 2012-05-08 |
| IL218756A0 (en) | 2012-06-28 |
| EP2485595A1 (en) | 2012-08-15 |
| CA2774992A1 (en) | 2011-04-14 |
| EP2485595A4 (en) | 2014-03-12 |
| IN2012DN02782A (https=) | 2015-09-18 |
| AU2010303811B2 (en) | 2013-01-24 |
| AU2010303811A1 (en) | 2012-04-19 |
| BR112012007829A2 (pt) | 2015-09-22 |
| JP2013507363A (ja) | 2013-03-04 |
| WO2011043942A1 (en) | 2011-04-14 |
| NZ599233A (en) | 2013-04-26 |
| RU2012118668A (ru) | 2013-11-20 |
| US20120202819A1 (en) | 2012-08-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5738871B2 (ja) | β３アドレナリン作動性受容体アゴニスト及び抗ムスカリン剤を用いる併用療法 | |
| JP4783867B2 (ja) | β３アドレナリン受容体アゴニストとしてのヒドロキシメチルピロリジン | |
| US8748433B2 (en) | β3 adrenergic receptor agonists | |
| ES2413504T3 (es) | Moduladores selectivos del receptor de andrógeno (SARM) y usos de los mismos | |
| MX2012005258A (es) | El uso de un compuesto de carbamoilo para el tratamiento del trastorno de deficit de atencion/hiperactividad. | |
| EP2427194B1 (en) | Pyrrolidine-derived beta 3 adrenergic receptor agonists | |
| WO2009140642A2 (en) | Tricyclic antagonists of prostaglandin d2 receptors | |
| CA3233408A1 (en) | Imidazopyridazine il-17 inhibitor compounds | |
| CN103140134B (zh) | 新吡咯烷衍生的β3肾上腺素能受体激动剂 | |
| JP2009512676A (ja) | ムスカリン性受容体アンタゴニストの医薬組成物 | |
| EP1937264A2 (en) | Combination therapy for the treatment of urinary frequency, urinary urgency and urinary incontinence |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20130920 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20140924 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20141205 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20150331 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20150422 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 5738871 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313111 |
|
| R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |